Rare cancers, defined as those affecting fewer than six people per 100,000 annually, represent a significant portion of all cancer diagnoses. Despite their rarity individually, collectively they account for approximately 22% of all cancer cases. Because of their low prevalence, they often receive less attention and fewer resources compared to more common cancers. This results in limited treatment options and poorer outcomes for patients.